3 results
The primary study objective is to assess the proportion of patients who remain within the IGF-I age adjusted normal limits with pasireotide LAR (60 mg) monotherapy, after 24 weeks of treatment.Secondary study objectives are assessment of the…
Hypothesis: Opsys will improve mild incontinence based on urine loss per 24 h measured by 24 h pad test.The main objective of this study is to test the effectiveness of Opsys in a group of selected subjects with minimal to mild (less than 30 g per…
Primary Study Objective:To assess the efficacy and safety of the co-administration of low-dose pegvisomant (40 mg, administered via subcutaneous injection given once a week) and long-acting somatostatin analogs (administered once monthly) on the…